FDA's third-party programme faltering for lack of company participants
This article was originally published in Clinica
Executive Summary
The FDA's evolving third-party inspection programme is moving slowly because the agency cannot get enough manufacturers to volunteer as host sites for supervised audits. "It's one of our limiting factors," explained Michael Rogers, director of the division of field investigations in the agency's office of regulatory affairs.